NCT00564746View on ClinicalTrials.gov

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 20, 2007

Primary Completion Date

October 26, 2007

Study Completion Date

October 26, 2007

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323

"\[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed."

Trial Locations (1)

EH33 2NE

GSK Investigational Site, Tranent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00564746 - To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males | Biotech Hunter | Biotech Hunter